ARAP1‐AS1 Overexpression Increases Diffuse Large B Cell Lymphoma Progression by Sponging miR‐508–5p to Activate the EMP1‐PI3K/AKT Pathway
Hematological Oncology · 2025
DOI: 10.1002/hon.70056 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hematological Oncology, 2025. Verfasst von Yamei Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The Dongtai Hospital of Nantong University, Dongtai, China. Hauptthemen laut MEDLINE: MicroRNAs, Lymphoma, Large B-Cell, Diffuse, Proto-Oncogene Proteins c-akt, Phosphatidylinositol 3-Kinases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Abstract (Originalsprache)
Diffuse large B cell lymphoma (DLBCL) is a type of common and fatal non‐Hodgkin lymphoma. This study aimed to detect the specific function of lncRNA ARAP1‐AS1 in DLBCL. The in vitro experiments were performed using RT‐qPCR, western blotting, MTT, colony formation, flow cytometry analysis, FISH, RNA pulldown, and luciferase reporter assays. A xenograft mouse model was used to evaluate tumor growth in vivo. ARAP1‐AS1 expression was upregulated in DLBCL tissues and cells. ARAP1‐AS1 knockdown inhibited DLBCL cell proliferation and promoted apoptosis. ARAP1‐AS1 activated PI3K/AKT signaling by upregulating EMP1 expression via miR‐508–5p. EMP1 overexpression markedly abolished the effect of ARAP1‐AS1 knockdown on DLBCL cell proliferation and apoptosis, and PI3K inhibitor reversed the effect of ARAP1‐AS1 overexpression on DLBCL cells. ARAP1‐AS1 knockdown inhibited DLBCL tumor growth and reduced Ki‐67, EMP1, and p ‐AKT expression in xenograft mouse models. ARAP1‐AS1 knockdown exerts anti‐tumor effect on DLBCL progression through the miR‐508–5p/EMP1/PI3K/AKT axis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, The Dongtai Hospital of Nantong University, Dongtai, China.
- Department of Traditional Chinese Medicine, The Dongtai Hospital of Nantong University, Dongtai, China.
- Department of Oncology, The Dongtai Hospital of Nantong University, Dongtai, China.
ORCID-Profile: Dongyun Gao
Zitieren
APA
Chen, Y., Ren, M., Zhu, L., Sun, T., Wang, X., Jiang, L., Zhou, L., & Gao, D. (2025). ARAP1‐AS1 Overexpression Increases Diffuse Large B Cell Lymphoma Progression by Sponging miR‐508–5p to Activate the EMP1‐PI3K/AKT Pathway. Hematological Oncology. https://doi.org/10.1002/hon.70056
Vancouver
Chen Y, Ren M, Zhu L, Sun T, Wang X, Jiang L, et al. ARAP1‐AS1 Overexpression Increases Diffuse Large B Cell Lymphoma Progression by Sponging miR‐508–5p to Activate the EMP1‐PI3K/AKT Pathway. Hematological Oncology. 2025. doi:10.1002/hon.70056
BibTeX
@article{Chen2025,
author = {Chen, Yamei and Ren, Minmin and Zhu, Lei and Sun, Ting and Wang, Xiaoyong and Jiang, Lingling and Zhou, Linlin and Gao, Dongyun},
title = {ARAP1‐AS1 Overexpression Increases Diffuse Large B Cell Lymphoma Progression by Sponging miR‐508–5p to Activate the EMP1‐PI3K/AKT Pathway},
journal = {Hematological Oncology},
year = {2025},
doi = {10.1002/hon.70056}
}
EUVIMED